UPDATE - Canaccord Genuity Initiates Coverage on Sunesis Pharmaceuticals (SNSS) with a Buy; Plan of Attack Against AML
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Price: $5.32 --0%
Rating Summary:
5 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 16
Rating Summary:
5 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 16
Join SI Premium – FREE
UPDATE - Canaccord Genuity initiates coverage on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) with a Buy. PT $4.00.
Analyst, George Farmer, said, "We see significant upside for SNSS shares on the potential of lead drug candidate vosaroxin under Phase III evaluation for treatment of relapsed/refractory acute myeloid leukemia (AML), an enormously high unmet medical need."
"Despite the recent succession of developmental and regulatory setbacks for novel AML therapeutics, we see several compelling differentiating factors that tip the risk/reward balance for vosaroxin as a potential game-changer. These include: 1) a seven-month Phase II median survival comparing well with historical r/r AML trial outcomes, 2) low rates of early mortality, which has routinely handicapped the benefit of other agents, 3) acceptable tolerability, and 4) a more favorable pharmacologic profile compared with other classes of agents used for disease treatment."
Analyst, George Farmer, said, "We see significant upside for SNSS shares on the potential of lead drug candidate vosaroxin under Phase III evaluation for treatment of relapsed/refractory acute myeloid leukemia (AML), an enormously high unmet medical need."
"Despite the recent succession of developmental and regulatory setbacks for novel AML therapeutics, we see several compelling differentiating factors that tip the risk/reward balance for vosaroxin as a potential game-changer. These include: 1) a seven-month Phase II median survival comparing well with historical r/r AML trial outcomes, 2) low rates of early mortality, which has routinely handicapped the benefit of other agents, 3) acceptable tolerability, and 4) a more favorable pharmacologic profile compared with other classes of agents used for disease treatment."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Starts Energy Fuels (UUUU) at Buy
- BTIG Starts FTAI Infrastructure (FIP) at Buy
- Benchmark Starts Beacon Roofing Supply (BECN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
